ArticleFrontiers in neuroinformatics2026
FUSION-AD: interpretable AI framework for risk assessment and subgroup discovery in Alzheimer's disease.
Article in Frontiers in neuroinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Alzheimer's disease (AD) is difficult to treat because of its multifactorial causes and heterogeneous progression across individuals. This study introduces FUSION-AD, a user-friendly and interpretable artificial intelligence framework for AD risk assessment and subgroup discovery. Methods: FUSION-AD integrates tree-based models, transformer-based neural networks, rule mining, and subgroup discovery to provide accurate and interpretable predictions. The framework was developed using the synthetic El Kharoua Alzheimer's Disease Dataset, which contains 2,149 structured clinical records from patients aged 60-90 years, with a mean age of 74.6 years and an average mini-mental state examination (MMSE) score of 21.7. The pipeline included data preprocessing, model benchmarking, feature-importance analysis, SHAP-based explanation, transformer attention analysis, association rule mining, and subgroup discovery. Results: Within the evaluated dataset, TabNet achieved the strongest point-estimate performance among the standalone benchmark models on the primary evaluation split, with an area under the receiver operating characteristic curve (AUROC) of 0.95, followed by XGBoost at 0.93, Random Forest at 0.92, and Logistic Regression at 0.89. Feature importance, SHAP values, and transformer attention consistently identified MMSE, Functional Assessment, and Memory Complaints as the most influential predictors. Association rule mining further highlighted diabetes and high body mass index as important risk factors. Subgroup discovery identified four clinical clusters, with prevalence ranging from 21.3 to 28.4%. Cluster 0 showed notable declines in daily functioning, with Functional Assessment decreasing by 2.1 and activities of daily living decreasing by 1.5, whereas Cluster 1 maintained daily functioning but showed increased behavioral symptoms. Discussion: FUSION-AD demonstrates that AD can be modeled in a way that balances predictive performance with interpretability within the studied dataset. The identified subgroup patterns suggest that lifestyle-driven profiles may benefit from preventive strategies, while cognitively impaired groups may require closer monitoring. These findings provide a foundation for future clinically oriented decision-support systems and require further validation using real-world clinical datasets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.